학술논문

A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non-small cell lung cancer.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; JUN 1 2022, 40 16, 1p. Supplement: S
Subject
Language
English
ISSN
15277755